Neosynephrine (Phenylephrine Hydrochloride)

Phenylephrine Hydrochloride, the active ingredient in Neosynephrine, is an alpha-1 adrenergic agonist presented as an ophthalmic solution for ocular use. It produces rapid pupil dilation to facilitate eye examinations and diagnostic procedures for patients undergoing routine clinical settings.

GNH USA supplies Neosynephrine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neosynephrine, an ocular alpha‑1 adrenergic agonist, is employed to induce mydriasis for various ophthalmic assessments.

Eye examination: provides pupil dilation to improve visualization of intraocular structures. Ocular diagnostic testing: enables clear view for imaging and laser procedures. Pre‑operative ocular assessment: facilitates thorough evaluation before surgery.

Phenylephrine Hydrochloride may cause ocular and systemic adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Transient ocular redness: mild irritation at the application site. - Temporary blurred vision: short‑term focus disturbance after dilation. - Mild eye discomfort: sensation of pressure or stinging. - Headache: occasional mild headache following administration.

Serious or Rare Side Effects: - Acute angle‑closure glaucoma: sudden increase in intraocular pressure requiring emergency care. - Systemic hypertension: significant rise in blood pressure, especially in susceptible patients. - Allergic reaction: rash, swelling, or severe eye inflammation.

When using Neosynephrine, consider the following precautions to ensure safe and effective application. - Assess intraocular pressure: avoid use in patients with narrow-angle glaucoma. - Review cardiovascular status: caution in individuals with uncontrolled hypertension. - Avoid concurrent mydriatics: limit combined use with other pupil‑dilating agents. - Monitor for systemic absorption: observe for signs of elevated blood pressure or tachycardia. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Phenylephrine Hydrochloride can interact with other medications; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis when combined with phenylephrine. - Non‑selective beta‑blockers: may blunt ocular vasoconstrictive response and affect systemic blood pressure.

Moderate Interactions (Monitor Closely): - Systemic sympathomimetics (e.g., epinephrine): additive cardiovascular stimulation. - Antihypertensive agents (e.g., ACE inhibitors): may reduce the drug’s systemic effects, requiring blood pressure monitoring. - Topical ocular decongestants: concurrent use may increase local vasoconstriction and discomfort.